Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors
Cancer Chemotherapy and Pharmacology, 07/03/2012
Clinical Article
Strickler JH et al. – Bevacizumab, everolimus, and panobinostat in combination at the lowest proposed doses did not have an acceptable safety and tolerability profile and did not consistently inhibit HDAC activity; therefore, do not recommend further evaluation.



